RARE Stock Gains on FDA Nod for Rare Disease Gene Therapy Genglycos
Shares of Ultragenyx Pharmaceutical RARE are rising in premarket trading today following the FDA's accelerated approval of DTX-401, an AAV8 gene therapy for glycogen storage disease type Ia (GSDIa). The therapy will be marketed in the United States as Genglycos (pariglasgene brecaparvovec-opnr) and is …